JNT-517

DRUG2 trials

Sponsors

Otsuka Pharmaceutical Development & Commercialization Inc., Otsuka Pharmaceutical Development & Commercialization, Inc.

Conditions

PhenylketonuriaPhenylketonuria (PKU)

Phase 3

A Long-Term Study of JNT-517 in Participants With Phenylketonuria

RecruitingNCT06628128

Otsuka Pharmaceutical Development & Commercialization, Inc.Phenylketonuria (PKU)

Start: 2025-08-11End: 2028-02-01Target: 240Updated: 2026-05-01

A Phase 3, Double-Blind, Randomized, Two-Period, Multicenter, Placebo-Controlled, Efficacy and Safety Study of JNT-517 for the Treatment of Participants with Phenylketonuria

RecruitingCTIS2024-519554-37-00

Otsuka Pharmaceutical Development & Commercialization Inc.Phenylketonuria

Start: 2026-01-16Target: 38Updated: 2025-11-14